triple agonist is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2025-08-27. Numbers and descriptions here follow the published literature rather than marketing material.
Retatrutide is an investigational synthetic peptide that acts as an agonist at three distinct G protein-coupled receptors. It combines activity at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor within a single molecule. This multi-receptor profile distinguishes it from earlier incretin-based compounds that engage one or two of these pathways. Researchers designed the molecule to test whether simultaneous activation produces greater metabolic effects than single or dual agonism alone.
The peptide backbone is chemically modified to resist rapid enzymatic breakdown in the body. A fatty acid side chain promotes binding to serum albumin, which slows renal clearance and supports an extended circulation time. These modifications allow less frequent administration than would be possible with an unmodified peptide. The precise contribution of glucagon receptor activation to the overall metabolic effect remains an area of active investigation, because glucagon raises glucose while also increasing energy expenditure.
Development has progressed through early- and mid-stage human studies in adults with obesity and with type 2 diabetes. Published phase 2 data reported reductions in body weight and improvements in glycemic markers over the treatment period. No regulatory agency has approved the compound for any indication, and it remains available only within controlled research settings. Whether benefits observed in trials translate into durable outcomes after treatment stops is not yet established.
Receptor activation produces downstream effects that differ by tissue. GLP-1 receptor signaling influences appetite regulation and insulin secretion in a glucose-dependent manner. GIP receptor activity contributes to metabolic handling of nutrients and may modulate adipose tissue. Glucagon receptor engagement raises energy expenditure and promotes hepatic lipid turnover, though the balance among these actions in humans is still being characterized. Preclinical models showed reductions in body weight and improved glycemic markers.
Clinical development has progressed through phase 2 trials in adults with obesity and type 2 diabetes, with phase 3 programs reported as ongoing. Reported outcomes include reductions in body weight and improvements in glycemic measures over defined treatment periods. Whether these effects translate into durable benefits after treatment ends remains an open question. Long-term safety data across broad populations are not yet complete, and regulatory decisions have not been announced.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Not a small molecule |
| Receptor targets | GLP-1, GIP, glucagon | Triple agonist activity |
| Appearance | White to off-white powder | Lyophilized solid |
| Solubility | Soluble in water | Also in aqueous buffers |
| Storage | −20 °C or below | Protect from light and moisture |
Clinical development has advanced through phase 2 trials in adults with obesity and type 2 diabetes. Reported phase 2 results described substantial average weight reduction over roughly forty-eight weeks of weekly dosing. A phase 3 program is ongoing to confirm efficacy and assess long-term safety. Because the compound has not received regulatory approval, it is not available as a prescription product. Public discussion of retatrutide often conflates trial findings with marketed status, an important distinction when interpreting coverage of the topic.
Retatrutide is a synthetic peptide developed as a single molecule that activates three distinct hormone receptors: GLP-1, GIP, and glucagon. The compound carries the internal designation LY3437943 and was engineered by modifying the backbone of glucose-dependent insulinotropic polypeptide. Its sequence incorporates non-natural amino acids and a fatty acid side chain that extends circulation time. The triple-agonist design aims to combine appetite suppression, improved insulin response, and increased energy expenditure in one agent. Published reports describe it as an investigational product rather than an approved medicine.
Each receptor contributes a different physiological effect. Activation of the GLP-1 receptor slows gastric emptying and reduces appetite signaling in the brain. GIP receptor activity influences insulin secretion and lipid handling, while glucagon receptor stimulation raises energy use and fat oxidation. Combining these pathways is intended to produce weight loss beyond what single- or dual-receptor agonists achieve. Researchers attribute the observed potency to simultaneous engagement of all three targets, though the exact contribution of each receptor to overall effect remains under investigation.
Retatrutide is an investigational peptide studied for obesity and type 2 diabetes. It is a single synthetic molecule designed to activate three metabolic receptors simultaneously. The compound belongs to the incretin mimetic family, a group of peptides that imitate gut hormones involved in appetite and glucose control. Its research code is LY3437943, and it remains under clinical study rather than cleared for routine medical use.
Acting as a triple agonist, the molecule binds the GLP-1, GIP, and glucagon receptors. GLP-1 activity slows gastric emptying and dampens appetite, while GIP signaling contributes to insulin sensitivity and fat metabolism. Glucagon receptor engagement raises energy expenditure and encourages fat breakdown, although it can also elevate blood glucose. Combining three pathways is intended to yield larger weight reduction than single or dual agonists, and researchers continue to examine how the balance among them shapes tolerability.
Pharmacologically the compound activates three receptors: GLP-1, GIP, and glucagon. GLP-1 and GIP signaling contribute to glucose-dependent insulin release, delayed gastric emptying, and reduced appetite, while glucagon receptor activation is associated with increased energy expenditure and hepatic fat oxidation. The single-molecule design is intended to keep these activities in one peptide rather than combining separate agents. Relative activity at each receptor differs, and the balance between them is a central question in interpretation. The glucagon component is partly offset by incretin-mediated insulin secretion, an interaction that remains incompletely characterized.
Development has progressed from single- and multiple-ascending-dose studies in healthy volunteers into larger randomized trials in adults with obesity, type 2 diabetes, and fatty liver disease. Early reports describe dose-dependent reductions in body weight and improvements in glycemic markers over treatment periods of several months. Whether the glucagon arm adds tolerability cost without added benefit is still debated. Long-term cardiovascular outcomes, effects after treatment stops, and performance in older or comorbid populations are open questions rather than settled findings. Approval status may change, so the current investigational label should be confirmed against regulatory sources.
Retatrutide is an investigational synthetic peptide developed under the code LY3437943, with a backbone derived from glucose-dependent insulinotropic polypeptide. Several non-proteinogenic residues, including alpha-aminoisobutyric acid, appear in that backbone, and a fatty diacid side chain attached through a linker extends circulation time. The molecule carries roughly thirty-nine amino acid units and a total mass near 4.7 kilodaltons. Administration is by subcutaneous injection once weekly. Published work uses both the name retatrutide and the code LY3437943.
Yeung Sik Yuen in accordance with Sub-Commission on the Promotion and Protection of Human Rights resolution 2001/36. He argues that the use of DU in weapons, along with the other weapons listed by the Sub‑Commission, may breach one or more of the following treaties: the Universal Declaration of Human Rights, the Charter of the United Nations, the Genocide Convention, the United Nations Convention Against Torture, the Geneva Conventions including Protocol I, the Convention on Conventional Weapons of 1980, and the Chemical Weapons Convention. Yeung Sik Yuen writes in Paragraph 133 under the title "Legal compliance of weapons containing DU as a new weapon":
== Contraindications == Pioglitazone cannot be used in patients with a known hypersensitivity to pioglitazone, other thiazolidinediones or any of the components of its pharmaceutical forms. It is ineffective and possibly harmful in diabetes mellitus type 1 and diabetic ketoacidosis. Its safety in pregnancy, lactation (breastfeeding) and people under 18 is not established. Given previous experiences with the related drug troglitazone, acute diseases of the liver are regarded as a contraindication for pioglitazone.
==== Tertiary structures ==== Many proteins share analogous structural elements that arose independently across different genomes. There are several examples of convergent protein motifs sharing similar arrangements of structural elements. Whole protein structures too have arisen through convergent evolution.
Chemical potential is the partial molar free energy. The potential, μi, of the ith species in a chemical reaction is the partial derivative of the free energy with respect to the number of moles of that species, Ni:
Sources: en.wikipedia.org
==== Amphetamines, harsher penalties, international obligations ==== During World War II (1939–1945), in addition to the widespread use of morphine, amphetamines entered military use to combat fatigue and improve morale. In the US, the Benzedrine brand was widely used in the military, and quickly became popular in the public for a variety of medical and recreational applications. Beginning in 1943, American soldiers could buy Benzedrine directly from the army on demand. Post-war, amphetamines were promoted as mood elevators and diet pills to great success; by 1945, an estimated 750 million tablets a year were being produced in the US, enough to provide a million people with a daily supply, a trend that grew during the 1950s and 1960s. Having failed to preserve world peace, the League of Nations ended post-war, transferring responsibilities to its successor, the United Nations. Anslinger, supported by Sharman, successfully campaigned to ensure that law enforcement and the prohibitionist view remained central to international drug policy. With the 1946 Lake Success Protocol, he helped to make sure that law enforcement was represented on the UN's new drug policy Supervisory Body (today's International Narcotics Control Board), and that it did not fall under a public health-oriented agency like the WHO. In the early 1950s, responding to "white suburban grassroots movements" concerned about dealers preying on teenagers, liberal politicians at state level cracked down on drugs.
=== Strontium === Strontium is naturally deposited in hydroxyapatite, the mineral component of bones and teeth, following its consumption in food and water. Each locale has a unique Sr isotope ratio and, therefore, the ratio found in a bone or enamel sample can be cross referenced against a record of environmental Sr ratios and assigned to a region. Dental enamel forms in childhood, therefore, Sr extracted from dental enamel reflects the environment in which an individual lived during infancy and childhood. Bone, however, is constantly being renewed and can therefore be used to infer the adult diet and location of the individual. As such, if the Sr ratios are the analogous in the bones and teeth, it can be inferred that an individual remained in the same general region throughout their life. If the ratios differ, the individual's birthplace and death place can be mapped, allowing inference of their movements. This has been applied to determine the functionality and significance of Stonehenge, finding that both the visitors and cattle used in feasting travelled great distances, with Sr ratios attributed to both Scotland and Wales.
In large cities, it is difficult to transmit power by overhead cables, so underground cables are used. But underground cables get heated and the resistance of the wire increases, leading to waste of power. Superconductors could be used to increase power throughput, although they would require cryogenic liquids such as nitrogen or helium to cool special alloy-containing cables to increase power transmission. Several feasibility studies have been performed and the field is the subject of an agreement within the International Energy Agency.
=== Legal action === In May 2019, in the first successful prosecution of top pharmaceutical executives for crimes related to the prescribing of opioids, the founder and four former executives of Insys Therapeutics Inc. were convicted by a federal jury in Boston in connection with bribing medical practitioners to prescribe Subsys, a highly-addictive sublingual fentanyl spray intended for cancer patients experiencing breakthrough pain, and for defrauding Medicare and private insurance carriers. The company declared bankruptcy about two weeks after they lost the case. Dozens of states are suing pharmaceutical companies, accusing them of causing the epidemic. Suits filed by almost 2,000 cities, counties, and tribal lands have been rolled into a single federal case scheduled to be heard in Fall 2019. In the first state case to reach a decision, on August 26, 2019, Oklahoma district court judge Thad Balkman found the pharmaceutical company Johnson & Johnson responsible for creating a "public nuisance" under state law, and ordered the company to pay a fine of $572 million. The company said they will appeal. Two other drug makers had previously settled with the state of Oklahoma. Purdue Pharma, the maker of OxyContin, agreed to a fine of $270 million in March 2019, and Teva Pharmaceuticals, which makes generic drugs, agreed to pay $85 million in May.
Biotextiles are specialized materials engineered from natural or synthetic fibers. These textiles are designed to interact with biological systems, offering properties such as biocompatibility, porosity, and mechanical strength or are designed to be environmentally friendly for typical household applications. There are several uses for biotextiles since they are a broad category. The most common uses are for medical or household use. However, this term may also refer to textiles constructed from biological waste products. These biotextiles are not typically used for industrial purposes. The term "biotextiles" derives from the combination of "bio," referring to biology or living organisms, and "textiles," indicating woven or fibrous materials. It encompasses the interdisciplinary field of biomedical textiles, which focuses on the design, fabrication, and application of textile materials in healthcare and biomedical engineering. Biotextiles made from mycelium, vegetable biomass, bacterial cellulose, and recombinant protein based fibers are used as an alternative to synthetic textiles to prevent and reduce the high greenhouse gas emissions, water pollution, and landfill waste from the textile industry. Biotextiles are also used within healthcare and the biomedical engineering field as implantable devices such as surgical sutures, hernia repair fabrics, arterial grafts, artificial skin and parts of artificial hearts.
Sources: en.wikipedia.org
Pyongyang (Korean: 평양관; MR: P'yŏngyanggwan) is a restaurant chain named after the capital of North Korea, with around 130 locations worldwide. The restaurants are owned and operated by the Haedanghwa Group.
Jainism teaches vegetarianism as moral conduct, as do some sects of Hinduism. Buddhism in general does not prohibit meat eating, but Mahayana Buddhism encourages vegetarianism as beneficial for developing compassion. Other denominations that advocate a vegetarian diet include the Seventh-day Adventists, the Rastafari movement, the Ananda Marga movement and the Hare Krishnas. Sikhism does not equate spirituality with diet and does not specify a vegetarian or meat diet.
== Composition == The basic composition of a sausage roll is sheets of puff pastry formed into tubes around sausage meat and glazed with egg or milk before being baked. They can be served either hot or cold. In the 19th century, they were made using shortcrust pastry instead of puff pastry. A vegetarian or vegan approximation of a sausage roll can be made in the same manner, using a meat substitute.
Once the heterologous protein has been fused with the bacterial cell surface protein, it is exposed to either an enzyme, a cell (expressing a target protein) or an antibody (usually fluorescently tagged), depending on the application of the experiment. The sample is then passed through a beam of light during FACS, in a very narrow stream of fluid so that only one cell can pass at a time, and the fluorescence emitted is detected. Information on the size of the cell can be obtained by the scattering of light and if binding of the heterologous protein with the target protein/cell has occurred, there will be more fluorescence emitted.
=== Gene drive === Research relevant to the development of gene drive controls of An. gambiae have been performed by Windbichler et al., 2007, Windbichler et al., 2008, Windbichler et al., 2011, Bernardini et al., 2014, Galizi et al., 2014, Hammond et al., 2016, Kyrou et al., 2018, Taxiarchi et al., 2019 and Simoni et al., 2020. For specific genes involved see § Genome above. These can all be used in pest control because they induce infertility.
Sources: en.wikipedia.org
Retatrutide is an investigational synthetic peptide that activates three metabolic receptors: GLP-1, GIP, and glucagon. It is being studied for obesity and type 2 diabetes. It has not been approved for clinical use.
Earlier incretin therapies engage one or two receptors. Retatrutide adds glucagon receptor activity, which may raise energy expenditure. Whether this produces larger clinical benefits is still being tested.
It has completed phase 2 trials and moved into later-stage evaluation. No regulator has granted approval. Access outside research settings is not authorized.
It is a synthetic peptide triagonist that engages GIP, GLP-1, and glucagon receptors. Investigational compounds in this class are studied for metabolic conditions rather than for a single organ system.